Sigma-Tau Pharmaceuticals (Sigma-Tau) has signed an exclusive US license agreement with Ireland-based Crosscare, to market and distribute Colief Infant Drops for the treatment of colic.
As part of the deal, Sigma-Tau will be responsible for the sales, marketing and distribution of Colief in the US.
Sigma-Tau has planned a re-launch of Colief at healthcare professionals as well as consumers in August 2014.
{iframe}http://otc.pharmaceutical-business-review.com/news/sigma-tau-crosscare-ink-deal-for-marketing-distribution-of-colief-in-us-120814-4342072{/iframe}